Riskpilot← Back to searchSign inGet full accessFarmakeut AB
ABActiveOrg 5590196696Säterigatan 122Retail sale of pharmaceutical products · NACE 4773Est. 20152 employees
Revenue 2025
SEK 9,3M
-1% vs 2024
EBITDA margin
5.4%
+123% vs 2024
Equity ratio
11.9%
Financial strength
Net profit 2025
SEK 307K
+5372% vs 2024
| Revenue | SEK 9,3M | -1% |
| EBITDA | SEK 500K | +123% |
| Net profit | SEK 307K | +5372% |
| Total assets | SEK 3,1M | +5% |
| Equity | SEK 369K | +493% |
| Employees | 2 | — |
Legal name
Farmakeut AB
Org number
5590196696
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
3 juli 2015
Share capital
SEK 50 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
På apoteket ska läkemedel, skönhetsprodukter säljas, dessutom skall det erbjudas olika patienttjänster som t.ex. blodtrycksmätning. De som har behov av mediciner, rådgivningen, och andra som behöver olika typ av vård produkter och skönhetsprodukter. Dessutom ska de vara i olika åldersgrupper.
Address
Säterigatan 122
Email
rasha.almofarji@farmakeut.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 618 | 11 551 | 10 610 | 9 431 | 9 328 |
| Staff expenses | — | −1 132 | −1 180 | −921 | −1 117 |
| EBITDA | 225 | 239 | 18 | 224 | 500 |
| Depreciation & amort. | −32 | −32 | −32 | −32 | — |
| EBIT | 193 | 207 | −14 | 192 | 500 |
| Net financials | −149 | −157 | −173 | −187 | −161 |
| Profit before tax | 44 | 49 | −187 | 6 | 339 |
| Tax | −10 | −11 | — | — | −33 |
| Net profit | 34 | 39 | −187 | 6 | 307 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 246 | 3 741 | 3 441 | 2 963 | 3 115 |
| Equity | 85 | 123 | 57 | 62 | 369 |
| Long-term debt | 2 696 | 2 539 | 2 314 | 2 263 | 2 008 |
| Short-term debt | 1 465 | 1 078 | 1 069 | 638 | 737 |
| Total debt | 4 161 | 3 617 | 3 384 | 2 901 | 2 745 |
EBITDA margin
5.4%
This company
15.8%
Market median
-66% vs market
20212025
Equity ratio
11.9%
This company
38.2%
Market median
-69% vs market
20212025
Return on equity
83.1%
This company
18.4%
Market median
+352% vs market
20212025
Net profit margin
3.3%
This company
8.1%
Market median
-59% vs market
20212025
Asset turnover
2.99×
This company
1.12×
Market median
+167% vs market
20212025
Debt / equity
7.44×
This company
0.62×
Market median
-1100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
XC Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Farmakeut AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Xuan Cuong Tu | Chief Auditor | 0 companies |
| Safaa Hamdan Al-Hilli | Deputy Board Member | 0 companies |
| Rasha Taleb Al-Mofarji | Board of Directors | 0 companies |